Q-omics provides the consensus-scored TENT5A profile across patient tissues and cancer cell-line models. TENT5A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, TENT5A is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TENT5A protein abundance shows 29,232 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LGG, COAD, and LSCC as cancer lineages where TENT5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TENT5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TENT5A survival associations across molecular data types. TENT5A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TENT5A RNA expression–survival associations across cancer types. High TENT5A expression shows unfavorable associations in LGG, BLCA, ESCA, LUSC and CESC, but favorable associations in LAML. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for TENT5A RNA expression.
This table summarizes TENT5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TENT5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TENT5A shows lower tumor expression in COAD, BLCA, READ and UCEC and higher tumor expression in KIRC and HNSC. The COAD box plot shows higher TENT5A RNA expression in normal versus tumor tissue (log2 FC = −1.264, t-test p < 0.001).
This table shows molecular features associated with TENT5A in patient tissues and cancer cell lines. In patient samples, TENT5A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TENT5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
